Treatment of breast cancer often exposes patients to many different drugs. Some of these drugs have toxic effects involving the cardiovascular system. This review provides an overview of the drugs most commonly used to treat breast cancer and their potential adverse impact on the cardiovascular system. (J Patient-Centered Res Rev. 2014;1:133-136.)

Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase (COX) enzymes, which exist in at least two isoforms, COX-1 and COX-2. Aspirin and older agents in this class are nonselective inhibitors of both COX-1 and COX-2. Newer agents termed "coxibs" are selective inhibitors of COX-2. Among the NSAID, only aspirin has been proven to significantly reduce cardiovascular risk, primarily th...

Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing anti-diabetic drugs that do not increase cardiovascular risk but might reduce the risk of cardiovascular events. Most type 2 diabetic patients die from cardiovascular causes despite the beneficial effects of blood pressure (BP) and lipid-lowering medicatio...

Infantile hemangiomas (IHs) are the most common benign vascular tumors in children. IHs are generally noticed within the first few days to months of life and are characterized by a rapid growth phase followed by an involution phase. Despite their benign and selflimited nature, some hemangiomas can be life-threatening, may cause complications such as ulceration and permanent disfigurement that r...

electivity toward cyclooxygenase (COX)-2 is usually dened by comparing the capacity of individual nonsteroidal nti-inflammatory drugs (NSAIDs) to inhibit in vitro or ex ivo the generation of thromboxane A2 (TXA2) through OX-1 in aggregating platelets with the capacity to inhibit rostaglandin (PG) E2 generation through COX-2, exressed in leukocytes after an inflammatory stimulus (1). his rather ...

Background: Cardiovascular disease is one of the chronic diseases with an increasing prevalence from year to year. The results Indonesia's basic health research (RISKESDAS 2018) showed that it was experienced by 2.9% population. Ensuring continuity drug availability very important in pharmacy services for this patient group. history use considered planning dan procurement products. Objective: T...

Objectives: The aim of the study was to determine the frequency and nature of oral manifestations secondary to use of cardiovascular drugs. Methods: Six hundred and three patients attending the general medicine departments of Bapuji hospital and Chigeteri Government hospital, Davangere, were evaluated for oral signs and symptoms like oral dryness, alteration in the taste or burning sensation an...

Oral anticoagulation has been limited to vitamin K antagonists (VKAs) for over 60 years. VKAs are effective and recommended for the prevention of venous and arterial thromboembolism in cardiovascular disease, but their pharmacodynamics are difficult to predict and the highly variable interindividual and intraindividual response to treatment accounts for the need of continuous monitoring. This p...

Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics. The sodium-glucose cotransporter 2 inhibitor, empagliflozin, markedly and rapidly reduced CV death and heart failure hospitalization, likely with hemodynamic/metabolic-driven mechanisms of action. More rece...